Digest Network Come funziona
Network
/
Società
Ph
Non verificato

PharmaEssentia USA Corporation

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

6 comunicati stampa

Guarda tutti i comunicati
24/11/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
PharmaEssentia Announces Publication of Phase 3 SURPASS-ET Results in The Lancet Haematology
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0
18/11/2025
Eventi
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
PharmaEssentia Announces Presentations at ASH 2025
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0
18/08/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Eventi
PharmaEssentia to Participate at Morgan Stanley 23rd Annual Global Healthcare Conference
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0
03/06/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0
20/05/2025
Eventi
Fiere
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
PharmaEssentia to Present Phase 3 SURPASS-ET Data in Oral Session at 2025 ASCO Annual Meeting
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0
04/03/2025
Industria
Biotecnologia
Farmaceutica
Salute
Oncologia
PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0